Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Gq pathway in uveal melanoma
$454,204Xu Chen · University Of California, San Francisco · R01 · FY2022 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
$454,144Andrew J Armstrong · Duke University · R01 · FY2022 · CA
Developing newly combined therapeutic strategies for mature B cell lymphoma
$454,144Jing Hong Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Spindle Assembly Checkpoint Silencing
$454,118Nicholas Gene Brown · Univ Of North Carolina Chapel Hill · R35 · FY2024 · GM
Spindle Assembly Checkpoint Silencing
$454,118Nicholas Gene Brown · Univ Of North Carolina Chapel Hill · R35 · FY2025 · GM
Spindle Assembly Checkpoint Silencing
$454,118Nicholas Gene Brown · Univ Of North Carolina Chapel Hill · R35 · FY2023 · GM
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma
$453,938Bryan Michael Burt · Baylor College Of Medicine · R37 · FY2021 · CA
Mechanisms of cell death in cutaneous melanoma
$453,931Andrew E Aplin · Thomas Jefferson University · R01 · FY2024 · CA
Regulation of DNA double-strand break repair pathway choice
$453,903Wolf-Dietrich Heyer · University Of California At Davis · R01 · FY2025 · CA
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
$453,875Markus Schober · New York University School Of Medicine · R01 · FY2021 · CA
Epigenetic Therapy for Thoracic Malignancies
$453,874David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance
$453,702Willy Hugo · University Of California Los Angeles · R01 · FY2023 · CA
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer
$453,632Raymond B Birge · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA
A Novel Target in The Tumor Myeloid Compartment for Hepatocellular Carcinoma
$453,620Xiang-Yang Wang · Virginia Commonwealth University · P01 · FY2025 · CA
A Novel Target in The Tumor Myeloid Compartment for Hepatocellular Carcinoma
$453,620Xiang-Yang Wang · Virginia Commonwealth University · P01 · FY2024 · CA
Epigenetic Regulation of Head and Neck Cancer Immune Evasion
$453,476Chao Lu · Columbia University Health Sciences · R01 · FY2025 · DE
Epigenetic Regulation of Head and Neck Cancer Immune Evasion
$453,476Chao Lu · Columbia University Health Sciences · R01 · FY2023 · DE
Mutational signature analysis: methods and applications to the clinic
$453,411Peter Park · Harvard Medical School · R01 · FY2025 · CA
Identification of genetic interactors of Brca2
$453,306Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
The Role of Schwann Cells in the Progression of Melanoma
$453,195Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Mutational signature analysis: methods and applications to the clinic
$453,188Peter Park · Harvard Medical School · R01 · FY2022 · CA
Checkpoints of TNF Gene Regulation
$452,973Anne Goldfeld · Boston Children'S Hospital · R01 · FY2014 · GM
DNA damage response and cancer immunity
$452,659Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
From the Past to the Future: Chimeric Antigen Receptor T cells for Lymphoid Malignancies
$452,562Joseph Anthony Fraietta · University Of Pennsylvania · P01 · FY2025 · CA
Modeling and targeting intrinsic and extrinsic features of Myc-driven Osteosarcoma
$452,549Jason Yustein · Emory University · R01 · FY2025 · CA